Evidence map›Paper›PMID 41941023›Full record

Observational studyAnnals of surgical oncology2026

Stage-Specific Prognostic Impact of Tumor Location in Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Analysis.

Shigeki Koterazawa, Toru Kanno, Yuki Kita, Takeshi Sano, Toshifumi Takahashi, Yuto Hattori, Go Kobori, Tomohiro Fukui, Toshiya Akao, Shotaro Hatano and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shigeki KoterazawaDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Toru KannoDepartment of Urology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Yuki KitaDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takeshi SanoDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Japan.
Toshifumi TakahashiDepartment of Urology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Yuto HattoriDepartment of Urology, Kobe City Medical Center General Hospital, Kobe, Japan.
Go KoboriDepartment of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan.
Tomohiro FukuiDepartment of Urology, Toyooka Hospital, Toyooka, Japan.
Toshiya AkaoDepartment of Urology, Rakuwakai Otowa Hospital, Kyoto, Japan.
Shotaro HatanoDepartment of Urology, Osaka Red Cross Hospital, Osaka, Japan.
Kaoru MurakamiDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takayuki SumiyoshiDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kimihiko MasuiDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takayuki GotoDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takashi Kobayashi *Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ryoichi SaitoDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. rsaito@kuhp.kyoto-u.ac.jp.
Daimonji Clinical Application Database Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic relevance of tumor location in upper tract urothelial carcinoma (UTUC), particularly the difference between renal pelvic and ureteral tumors, remains controversial. This study aimed to clarify the impact of tumor location on stage-specific survival and recurrence patterns following radical nephroureterectomy (RNU), using a large multi-institutional cohort.

methodsPatients diagnosed with UTUC who underwent RNU between 2003 and 2023 were retrospectively reviewed and categorized into the renal pelvic urothelial carcinoma (RPUC) group or the ureteral urothelial carcinoma (UUC) group. Propensity score matching was then applied to adjust for baseline clinicopathological factors between the RPUC and UUC groups. Cancer-specific survival (CSS), nonurothelial tract recurrence-free survival (NUTRFS), and recurrence patterns were compared, with subgroup analyses being conducted according to pathological T stage (pTa/Tis/T1, pT2, and pT3/4).

resultsWe retrospectively analyzed 1,367 patients with UTUC. After propensity score matching, 5-year CSS and NUTRFS tended to be lower in the UUC group than in the RPUC group (CSS: 72% vs. 79%, p = 0.069; RFS: 55% vs. 62%, p = 0.072). In pT2 disease, outcomes were significantly worse in the UUC group (5-year CSS: 68% vs. 90%, p = 0.024; NUTRFS: 49% vs. 68%, p = 0.021). The UUC group also had significantly higher local recurrence rates at both pT2 and pT3/T4. In contrast, the RPUC group tended to have more distant metastases at pT3/4.

conclusionsTumor location in UTUC may influence stage-specific outcomes. These differences in outcomes underscore the need for individualized stage-specific management.

Indexed as

Carcinoma, Transitional CellKidney NeoplasmsKidney PelvisNeoplasm Recurrence, LocalNephroureterectomyUreteral NeoplasmsAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPrognosisPropensity ScoreRetrospective StudiesNephroureterectomyPrognosisRenal pelvisSurvivalUpper tract urothelial carcinomaUreter

Identifiers

PMID41941023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.